<DOC>
	<DOCNO>NCT01746147</DOCNO>
	<brief_summary>The ALLIVE ( ALLogeneic Iron inVEstigators ) trial aim quantify extent dynamic change LPI occurrence condition identify LPI-predictive peri-transplant parameter . Further point interest improvement systemic iron overload ( SIO ) diagnostics correlation different SIO parameter outcome transplantation . The result trial help design prospective interventional study address therapeutic option patient risk SIO-associated toxicity allogeneic stem-cell transplantation ( allo-SCT ) .</brief_summary>
	<brief_title>Assessment Body , Liver Labile Plasma Iron Their Association With Outcome Immunological Recovery Myelodysplastic Syndrome ( MDS ) Acute Myeloid Leukemia ( AML ) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE ( ALLogeneic Iron inVEstigators ) Observational Trial</brief_title>
	<detailed_description />
	<criteria>Age &gt; = 18 year time signing informed consent form Signed informed consent Diagnosis AML MDS accord WHO classification Planned allogeneic stem cell transplantation reduce intensity myeloablative conditioning relate unrelated donor At risk iron toxicity define ferritin &gt; 500 ng/ml and/or history 10 RBC transfusion prior alloSCT Claustrophobia mental disorder make MRI image unbearable patient Cardiac pacemaker , metal implant splinter contraindication MRI More 1 Human leukocyte antigen ( HLA ) allele antigen mismatch donor recipient Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Patients history chronic drug abuse another illness allow patient assess nature and/or possible consequence study Patients likely follow trial protocol ( lack willingness cooperate )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
	<keyword>allogeneic SCT</keyword>
</DOC>